Sanofi's first big tri­al for top can­cer drug ends in set­back

One of Sanofi’s top late-stage prospects has failed its first ma­jor test in breast can­cer, dim­ming block­buster hopes even as the French drug­mak­er dou­bles down on on­col­o­gy.

Sanofi had tout­ed am­cen­es­trant as a “po­ten­tial­ly trans­for­ma­tive” prod­uct. In the AMEERA-3 tri­al, though, it did not meet the pri­ma­ry end­point of im­prov­ing pro­gres­sion-free sur­vival over en­docrine treat­ment of physi­cian’s choice.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER